Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Neoplasms, Glandular and Epithelial
  • Ovarian Neoplasms

abstract

  • The addition of bevacizumab to this IP regimen is feasible; however, bevacizumab may increase the risk of bowel obstruction/perforation. The observed median PFS is similar to that seen with IP/IV chemotherapy alone.

publication date

  • December 10, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3667619

Digital Object Identifier (DOI)

  • 10.1200/JCO.2011.36.1352

PubMed ID

  • 22067389

Additional Document Info

start page

  • 4662

end page

  • 8

volume

  • 29

number

  • 35